Top Tech Companies (145)
Amber Therapeutics is a University of Oxford spinout developing next-generation, intelligent bioelectrical therapies to transform clinical outcomes in patients with functional disorders of the peripheral nervous system. Amber’s approach leverages closed-loop intelligence to create ‘synthetic reflex arcs’ that can sense, interpret, adapt and respond to a patient’s individual signals thereby restoring normal physiological function. Amber Therapeutics was founded by a...
Smith+Nephew is a global medical technology company. We design and manufacture technology that takes the limits off living. We support healthcare professionals to return their patients to health and mobility, helping them to perform at their fullest potential. From our first employee and founder, T.J. Smith, to our team today, it’s our people who make Smith+Nephew a unique place. Yes, we love...
Complement Therapeutics GmbH (CTx) is an early-stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade. Our lead investigational product (CTx001) is being evaluated as a potential gene...
QIO Technologies is a sustainability tech company delivering Industrial IoT AI software products supporting energy-intensive and asset-heavy Industrial, Data Center and Telecom companies to reduce greenhouse gas emissions, improve energy efficiency, and accelerate operational sustainability. QiO developed its Foresight Sustainability Suite™ in response to the difficulties faced by industry in leveraging large, disparate sources of operational data to reduce GHG...
Personalised cancer therapeutics platform pioneered at Mount Sinai Medical Center
Autolus is a CAR T cell therapy company. We are applying our extensive programming capabilities to develop advanced autologous T cell therapies that have the potential to deliver life-changing therapies to patients with cancer and autoimmune diseases.
LabGenius is the first biopharmaceutical company developing next generation protein therapeutics using a machine learning-driven evolution engine (EVA™). Our protein engineering platform integrates several bleeding edge technologies from the fields of machine learning, synthetic biology and robotics.
We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.
Biocentis is an Imperial College London spin-out on a mission to develop eco-friendly genetic solutions to effectively and safely control the dangerous insect species that spread disease to humans, reduce biodiversity, or threaten food security. We leverage CRISPR to develop self-limiting gene drive technologies that are biological, environmentally friendly, and can be tailored to obtain levels of control that are...
At Touchlight we are revolutionising DNA. Our Company and technology is built on the conviction that DNA is fundamental to the future of medicine. By moving away from today's restrictive biological approaches, we have made DNA simple. Our unique dbDNA™ (or "doggybone" DNA) vector is optimised for use in advanced genetic medicines, being safer and more efficacious than conventional plasmid DNA....
Let's transform lives together and work towards a functional, confident smile on every face
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development...
MicrofluidX presents the Cyto Engine, a unified bioreactor and data platform for cell and gene therapy research, development, and manufacturing
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business...
Winner of the 2022 Prix Galien UK Award for "Best Digital Health Solution". The equivalent of the Nobel Prize within Life Science. At behold.ai we utilise cutting-edge science to pioneer new forms of diagnostic medicine; this revolutionary approach to healthcare is a step change in the treatment and prevention of diseases, benefiting patients on a global scale
Ascend is an end-to-end gene therapy development partner with deep expertise in gene therapy development and commercialization. We offer unparalleled collaboration while working to develop your products from the bench through the clinic and beyond. Scientific innovation driven by quality and responsibility are at the core of our business. To set a new standard in the industry, we have invested...
biomodal is an omics based life-sciences technology and analytics company delivering products that bring the dynamism of our ever-changing biology into focus. Our duet multiomics solution enables more epigenetic information from a single, low input DNA library without complex, resource intensive bioinformatics or harsh chemical treatment. Our single-base-resolution, phased sequencing approach unlocks the combinatorial power of genetic and epigenetic information...
Genz is a spin-off biotech company developing novel solutions from in vitro diagnostics to therapeutics. Our mission is to deliver a consistent stream of innovative, affordable, and accessible diagnostic solutions and make a remarkable impact on people’s lives. We’re focused on sustainable growth and addressing the world’s pressing health challenges; therefore, we’re able to create value for both our patients...
Epsilogen is a global leader in the development of immunoglobulin (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life. The company's lead programme targets the folate receptor alpha (FR alpha) and an anti-FR alpha IgE antibody is currently...
